Get 40% Off
🔥 This hedge fund gained 26.16% in the last month. Get their top stocks with our free stock ideas tool.See stock ideas

Tissue Regent: Keeping The Beat (Of Next-Generation Heart Valves)

Published 09/16/2016, 01:49 AM
Updated 07/09/2023, 06:31 AM
TRX
-

Keeping the beat - next-generation heart valves
Tissue Regenix Group Plc (LON:TRX)’s investment story is built on dCELL, a versatile regenerative medical technology and its potential applications across the subsectors: cardiac, wound care and orthopaedics. The cardiac division has a proven technology with the broadest clinical experience, with 10 years of clinical follow-up data recently presented. We maintain our sum-of-the-parts valuation at £338m.

Tissue Chart

First dCELL human heart valve licenced to JV
In January 2016 Tissue Regenix entered into a joint venture (JV) agreement with a German tissue bank. It has received a non-exclusive licence to its human dCELL heart valves and DermaPure. The JV provides ethical access to human tissue (supply is a limiting factor to commercialisation) and will pursue the regulatory submissions in Germany, potentially leading to a first product launch of dCELL heart valves in 2017. Tissue Regenix intends to replicate this business model to commercialise in other EU jurisdictions in the future.

To read the entire report Please click on the pdf File Below

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.